en
Feedback

Don't get caught by a cheater! Telemetrio finds and tags such channels πŸ‘‰ If you want to see the tag, subscribe

Hidden Multibagger Stocks by Devendra (RA: INH000026488)

Hidden Multibagger Stocks by Devendra (RA: INH000026488)

Open in Telegram

Disclaimer: I am a SEBI Registered Research Analyst (RA: INH000026488). All stocks, market updates, and investment-related information shared in this channel are strictly for educational and informational purposes only.

Show more

πŸ“ˆ Analytical overview of Telegram channel Hidden Multibagger Stocks by Devendra (RA: INH000026488)

Channel Hidden Multibagger Stocks by Devendra (RA: INH000026488) (@hiddenmultibaggerstocks_devendra) in the English language segment is an active participant. Currently, the community unites 10 054 subscribers, ranking 11 310 in the Economy & Finance category and 37 191 in the India region.

πŸ“Š Audience metrics and dynamics

Since its creation on Π½Π΅Π²Ρ–Π΄ΠΎΠΌΠΎ, the project has demonstrated rapid growth, gathering an audience of 10 054 subscribers.

According to the latest data from 07 November, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 10 over the last 30 days and by 2 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 26.60%. Within the first 24 hours after publication, content typically collects 20.23% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 2 675 views. Within the first day, a publication typically gains 2 034 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 13.
  • Thematic interests: Content is focused on key topics such as multibagger, bull, wealth, investor, rally.

πŸ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
β€œDisclaimer: I am a SEBI Registered Research Analyst (RA: INH000026488). All stocks, market updates, and investment-related information shared in this channel are strictly for educational and informational purposes only.”

Thanks to the high frequency of updates (latest data received on 08 November, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Economy & Finance category.

10 054
Subscribers
+224 hours
+107 days
+1030 days
Posts Archive
As highlighted in my latest YouTube video and repeatedly shared on our Telegram channel, the next sector that could lead this bull run is the Pharma sector. Many pharma stocks have already started outperforming the broader market, indicating strong buying interest. Some of the leading outperformers include: β€’ Jagsonpal Pharmaceuticals β€’ Morepen Labs β€’ Shilpa Medicare β€’ Gland Pharma β€’ Supriya Lifescience β€’ Gufic Biosciences β€’ Orchid Pharma β€’ Kwality Pharmaceuticals β€’ Bliss GVS Pharma β€’ Beta Drugs β€’ Senores Pharmaceuticals β€’ Fredun Pharmaceuticals

"Sterlite Technologies" , a data center theme stock, is currently undergoing a healthy consolidation after its recent sharp rally. This is a normal price action seen in every strong stock after a significant move in a short period. However, many social media experts often misinterpret such consolidation as a major crash or underperformance and advise investors to exit. In reality, during a bull market, leading stocks from outperforming sectors can continue their uptrend for a long time after periodic consolidations. That is why only investors who truly understand the difference between bull and bear markets have the conviction to hold potential multibagger stocks through temporary consolidations instead of exiting in panic.πŸ’₯πŸ’₯

As I have been saying, the market is likely to remain sideways until Q1 results are announced. Right now, the market is waiting to see which sectors and companies will deliver outstanding results. Many industries were affected over the last 2–3 months due to concerns surrounding the Strait of Hormuz and elevated crude oil prices. The impact of these factors is expected to be reflected in Q1 earnings. TCS will announce its Q1 results on 9th July, along with management commentary. These results will be crucial in determining the near-term outlook for the IT sector and will provide insights into the impact of AI on IT companies. This is why the stock market does not move based on daily news headlines, as many people believe. Even though the Strait of Hormuz is open, the war concerns have eased, and crude oil prices have declined, the market is still moving sideways. To succeed in the stock market, you need to think differently and understand how the market actually works. If you simply follow social media news and popular predictions, it becomes very difficult to generate exceptional returns because the market often moves against the consensus.πŸ’₯πŸ’₯

"INOX INDIA " New Multibagger stock strong recovery after recent fall..πŸš€πŸš€

"HFCL " Multibagger stock continue to outperform.πŸš€πŸš€ From 117 to 218 @ 86% Gain..

Yash Highvoltage – Multibagger stock continue to outperform...πŸš€πŸš€

Why has Acutaas Chemicals delivered multibagger returns? The answer lies in its consistently improving operating performance. The company's operating profit margin has increased quarter after quarter: β€’ 25% β†’ 31% β†’ 38% β†’ 42% When a company's operating margin keeps expanding over a short period, it reflects strong business execution and improving profitability. The market often rewards such companies with higher valuations. We identified this opportunity when the stock was around β‚Ή800 after the management provided strong growth guidance for its CDMO business. The company also entered high-growth segments such as battery chemicals and semiconductor chemicals, further strengthening its long-term growth story. Acutaas Chemicals has become one of the first pharma-related companies to deliver massive returns in FY2025–26. We believe the broader pharma sector rally has now begun, and this positive trend could continue. Many investors ask how we are able to hold multibagger stocks for such a long time. The answer is simpleβ€”we first understand the business, not just the stock price. Every quarter, we closely analyse the company's results and management commentary before deciding whether to continue holding or exit. If you don't understand the underlying business growth, you are likely to sell a winning stock after small price fluctuations and miss the real wealth creation. This is also why we do not give fixed price targets or stop-loss levels. No one can predict how long a stock will outperform. Ultimately, a stock's long-term performance depends on the company's business growthβ€”not just technical charts.πŸ‘†

" Acutaas Chemicals " Multibagger stock Fired....πŸš€πŸš€ This stock is well-positioned to participate in the upcoming rally in the pharmaceutical sector and has the potential to outperform as the sector gains momentum...πŸ’ƒπŸ’ƒπŸ’ƒ

🎯 One of our Premium Channel members' portfolio. "Acutaas Chemicals" has delivered an outstanding 200% return after more than one year of patient holding. This is a reminder that you don't need dozens of multibagger stocks to create wealth. Just 4–5 high-quality multibagger investments, bought near their bottom with meaningful capital and held with patience, can generate significant long-term wealth. We had recommended Acutaas Chemicals in free channel as well as our Diwali Muhurat Pick in 2025 at around β‚Ή1,600. Patience + Conviction + Buying at the right valuation = Wealth Creation.πŸ‘†

"Aditya infotech " Multibagger Stock was in a consolidation phase after sharp rally. The stock now appears to be getting ready for its next move. πŸš€

"Aditya infotech " Stock was in a consolidation phase after sharp rally. The stock now appears to be getting ready for its next move. πŸš€

"Acutaas Chemicals" is emerging as one of the biggest wealth-creating stocks of FY 2025–26. The stock continues to show strong momentum and has the potential to generate significant returns for long-term investors.πŸš€πŸš€ From 910 to 3364 @ 270 %

As I have repeatedly said in many of my YouTube videos, the stock market does not move based on day-to-day news. In fact, it often moves against the expectations of social media experts. In April 2026, the Smallcap Index rallied sharply, and many stocks delivered excellent returns. At that time, the Hormuz Strait was closed, the war was ongoing, crude oil was expected to cross $100, and many experts were predicting a major market crash. Now in June , the war is over, the Hormuz Strait has reopened, and crude oil prices have fallen. Despite all this positive news, the market is not moving much, even though many experts were expecting a good rally. This is exactly why I keep saying that the market does not follow daily news or popular opinions on social media. One week ago, I clearly said that the next rally would begin only after the Q1 results, and that there would be very little movement in stocks before then. As you can see, that is exactly what has happened. Our approach is completely different. We don't make predictions based on daily headlines. Instead, we analyse the market with a different method and focus on the next 1–2 months. That is why most of our market predictions have been accurate.

πŸ‘‰As I mentioned in my YouTube video and repeatedly over the past week, the market is likely to remain sideways with no much movement in the stocks until Q1 results begin to be announced. Today, the pharmaceutical sector is the clear outperformer. In my latest YouTube video, I explained that the Pharma Index was on the verge of a breakout, and today's price action is supporting that view. The following pharma stocks continue to outperform: 1. Bliss GVS 2. Beta Drugs 3. Kwality Pharmaceuticals 4. IOL Chemicals & Pharmaceuticals 5. Ind-Swift Laboratories 6. Senores Pharmaceuticals 7. Sakar Healthcare 8. KMC Speciality Hospitals 9. Venus Remedies 10. Gufic Biosciences 11. Marksans Pharma 12. Gland Pharma